AstraZeneca is still waiting for the US drug regulator to approve the restart of the clinical trial of its potential COVID-19 vaccine in the United States almost three weeks after it was paused due to safety concerns.
The US trial of AstraZeneca’s COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programs outside of the United States have resumed.
“We are discussing with other companies as an industry what information we can offer without compromising patient privacy but also without compromising the trial itself,” said the CEO.
Soriot also said that tests of the vaccine prototype on children had not started yet.
The British trial , launched in May seeking more than 12,000 volunteers, will have one out of 11 subgroups with children 5 to 12 years of age.